Axon Enterprise (NASDAQ:AXON) Rating Increased to Strong-Buy at Zacks Research

Axon Enterprise (NASDAQ:AXON) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. TD Cowen dropped their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Craig Hallum reissued a “buy” rating and issued a $820.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Finally, UBS Group dropped their price objective on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Price Performance

Shares of AXON opened at $398.44 on Tuesday. Axon Enterprise has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The firm’s 50 day moving average price is $421.95 and its 200 day moving average price is $506.34. The company has a market cap of $32.11 billion, a P/E ratio of 160.02, a PEG ratio of 7.13 and a beta of 1.44. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. During the same period in the prior year, the firm earned $1.47 EPS. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. On average, research analysts forecast that Axon Enterprise will post 1.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total value of $5,002,400.00. Following the transaction, the chief executive officer directly owned 3,090,997 shares of the company’s stock, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeri Williams sold 157 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total transaction of $76,930.00. Following the completion of the transaction, the director directly owned 1,159 shares in the company, valued at $567,910. This trade represents a 11.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 13,855 shares of company stock worth $7,109,828. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Arkadios Wealth Advisors boosted its stake in Axon Enterprise by 3.5% during the 1st quarter. Arkadios Wealth Advisors now owns 3,792 shares of the biotechnology company’s stock worth $1,610,000 after purchasing an additional 127 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Axon Enterprise by 10.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,736 shares of the biotechnology company’s stock worth $737,000 after purchasing an additional 162 shares during the period. Empowered Funds LLC boosted its stake in Axon Enterprise by 90.1% during the 1st quarter. Empowered Funds LLC now owns 6,320 shares of the biotechnology company’s stock worth $2,684,000 after purchasing an additional 2,996 shares during the period. Evelyn Partners Investment Management LLP boosted its stake in Axon Enterprise by 42.6% during the 1st quarter. Evelyn Partners Investment Management LLP now owns 1,550 shares of the biotechnology company’s stock worth $658,000 after purchasing an additional 463 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd boosted its stake in Axon Enterprise by 18.6% during the 1st quarter. Evelyn Partners Investment Management Services Ltd now owns 862 shares of the biotechnology company’s stock worth $366,000 after purchasing an additional 135 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s Connected Devices segment is benefiting from strong demand for TASERs, body cameras, and counter-drone products, reinforcing the company’s revenue growth story. Strength in Connected Devices Unit Drives Axon: Can the Momentum Sustain?
• Positive Sentiment: The company is highlighting AI and drone growth as part of its strategy to become a broader “operating system” for public safety, which could expand long-term recurring revenue opportunities. Axon Enterprise touts AI, drone growth in push to be public safety’s operating system
• Positive Sentiment: Investors are also reacting to Axon’s strong Q1 2026 results, which included revenue of $807.35 million and higher full-year revenue growth guidance of 30%–32%, signaling sustained momentum. Should Axon’s Strong Q1 2026 Results and Higher Guidance Require Action From Axon Enterprise (AXON) Investors?
• Neutral Sentiment: Axon’s presentation at the J.P. Morgan Technology, Media and Communications Conference kept management’s growth story in front of investors, but the item itself did not include a major new catalyst. Axon Enterprise, Inc. Presents at J.P. Morgan Conference Transcript
• Neutral Sentiment: Commentary from Jim Cramer framed AXON as a high-multiple stock that may remain sensitive to bond yields and market sentiment, which is a reminder of valuation risk rather than a direct company-specific negative. Jim Cramer on Axon: “I Still Think That This Market Does Not Like High Multiple Stocks”
• Negative Sentiment: One market report noted AXON underperformed some competitors despite gains, suggesting investors may be weighing its rich valuation against the strong growth outlook. Axon Enterprise Inc. stock underperforms Monday when compared to competitors despite daily gains

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.